- Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
-
Theodoraki E, Orfanoudaki E, Foteinogiannopoulou K, Legaki E, Gazouli M, Koutroubakis IE
- KMID: 2521609
- Intest Res.
- 2021 Oct;19(4):461-467.
- doi: 10.5217/ir.2020.00042
Background/Aims: The measurement of infliximab trough levels (IFX-TLs) in patients with inflammatory bowel disease (IBD) is performed to optimize treatment. However, the association between the development of adverse events (AEs)... -
- CITED
-
- Close
- SHARE
-
- Close
- Polymorphisms of the BARX1 and ADAMTS17 Locus Genes in Individuals With Gastroesophageal Reflux Disease
-
Argyrou A, Legaki E, Koutserimpas C, Gazouli M, Papaconstantinou I, Gkiokas G, Karamanolis G
- KMID: 2454642
- J Neurogastroenterol Motil.
- 2019 Jul;25(3):436-441.
- doi: 10.5056/jnm18183
BACKGROUND/AIMS: Gastroesophageal reflux disease (GERD) represents a common condition having a substantial impact on the patients' quality of life, as well as the health system. According to many studies, the... -
- CITED
-
- Close
- SHARE
-
- Close
